[A study on the subjective compliance and acceptance of oral lanzoprazole in traumatology. The ECOFT-TR Study].

OBJECTIVE

To assess compliance with oral lansoprazole disintegrating tablets (LODT) in patients treated by traumatology specialists.

MATERIAL AND METHOD

A multicenter, observational, cross-sectional study involving 370 traumatology specialists and patients aged 18 or more. Study logistics were sponsored by Almirall Laboratories, S.A.; neither investigators nor patients received any economic compensation for their participation. Patient subjective compliance with LODT was assessed with the Haynes Sackett test. Acceptability was based on patients' global assessments of the drug's organoleptic characteristics and properties of use, and preferences regarding previous treatments, recorded by means of a self-administered 15-item ad hoc questionnaire with a 2-5-point Likert-type scale, that patients fulfilled once.

RESULTS

One thousand and eighty five patients were evaluable for the main endpoint. Mean age was 56.09±13.8 years; 56.77% were women. Mean treatment duration was 51.24±38.8 days. 94.74% of the patients complied with the treatment. Mean percentage of compliance was 94.5±12.12; 91.09% of patients rated the treatment as «acceptable or highly acceptable». No significant differences were observed between compliant and non-compliant patients in terms of demographic or clinical variables. Mean percentage of compliance was significantly higher among patients without concomitant illness or treatment and without difficulties in taking tablets. One non-serious adverse reaction was reported in one (0.09%) patient.

CONCLUSIONS

Compliance with lansoprazole orally disintegrating tablets was high. Patients reported that this formulation improved their compliance and that they preferred LODT to previous medication. Tolerability was excellent.